DE69012840T2 - Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben. - Google Patents

Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben.

Info

Publication number
DE69012840T2
DE69012840T2 DE69012840T DE69012840T DE69012840T2 DE 69012840 T2 DE69012840 T2 DE 69012840T2 DE 69012840 T DE69012840 T DE 69012840T DE 69012840 T DE69012840 T DE 69012840T DE 69012840 T2 DE69012840 T2 DE 69012840T2
Authority
DE
Germany
Prior art keywords
group
hydrogen
adenosine derivatives
blood pressure
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69012840T
Other languages
English (en)
Other versions
DE69012840D1 (de
Inventor
Toshio Yamada
Ken-Ichi Kageyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69012840D1 publication Critical patent/DE69012840D1/de
Publication of DE69012840T2 publication Critical patent/DE69012840T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69012840T 1989-01-11 1990-01-11 Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben. Expired - Fee Related DE69012840T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1005658A JPH0725785B2 (ja) 1989-01-11 1989-01-11 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物

Publications (2)

Publication Number Publication Date
DE69012840D1 DE69012840D1 (de) 1994-11-03
DE69012840T2 true DE69012840T2 (de) 1995-03-16

Family

ID=11617214

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69012840T Expired - Fee Related DE69012840T2 (de) 1989-01-11 1990-01-11 Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben.

Country Status (7)

Country Link
US (2) US4985409A (de)
EP (1) EP0378518B1 (de)
JP (1) JPH0725785B2 (de)
AT (1) ATE112285T1 (de)
DE (1) DE69012840T2 (de)
DK (1) DK0378518T3 (de)
ES (1) ES2064700T3 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298508A (en) * 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5914396A (en) * 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US5792844A (en) * 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5618704A (en) * 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5623070A (en) * 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5677437A (en) * 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
JP2505085B2 (ja) * 1990-09-25 1996-06-05 ローヌ−プーラン ローラー インターナショナル （ホウルディングス） インコーポレイテッド 抗昇圧および抗虚血特性を有する化合物
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US5206222A (en) * 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
WO1994002497A1 (en) * 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sulfo-derivatives of adenosine
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5596094A (en) * 1994-05-26 1997-01-21 Sandoz Ltd. Process for preparing 2' -0- alkyl adenosine derivatives
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
TR200100410T2 (tr) 1998-06-23 2001-06-21 Glaxo Group Limited 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri.
JP3619017B2 (ja) 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
EP1018514B1 (de) 1998-07-22 2004-05-12 Daiichi Suntory Pharma Co., Ltd. Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
AU2006214233A1 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CN100355769C (zh) * 2005-11-16 2007-12-19 华东师范大学 2＇－甲氧基腺苷的制备方法
WO2009032057A2 (en) 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
WO2017137528A1 (en) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130136C (de) * 1966-10-20
NL7203984A (de) * 1971-04-10 1972-10-12
DE2136624A1 (de) * 1971-07-22 1973-02-08 Boehringer Mannheim Gmbh N (6)-substituierte adenosin-derivate und verfahren zur herstellung derselben
US3922261A (en) * 1972-06-21 1975-11-25 Merck Patent Gmbh Adenosine derivative
DE2628202A1 (de) * 1976-06-23 1977-12-29 Max Planck Gesellschaft Verfahren zur herstellung von 2'-substituierten-d-ribofuranosylpurinderivaten
US4501735A (en) * 1983-12-05 1985-02-26 Warner-Lambert Company N6-(1- and 2-benzocycloalkyl) adenosines
US4657897A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines for treating pain
US4657898A (en) * 1984-06-22 1987-04-14 Warner-Lambert Company N6 -substituted adenosines and method of use
US4616003A (en) * 1984-10-26 1986-10-07 Warner-Lambert Company N6 -dihydroxypropyladenosines
AU577743B2 (en) * 1984-10-26 1988-09-29 Warner-Lambert Company N6-benzopyrano and benzothiopyrano adenosines
US4614732A (en) * 1984-10-26 1986-09-30 Warner-Lambert Company N6 -acenaphthyl adenosines and analogs thereof
ZA858154B (en) * 1984-10-26 1986-06-25 Warner Lambert Co N6-substituted deoxyribose analogs of adenosines
JPS61103892A (ja) * 1984-10-26 1986-05-22 ワーハー‐ランバート・コンパニー Ｎ↑６‐アセナフチルアデノシン類およびそれらの類縁体
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4791103A (en) * 1985-02-08 1988-12-13 Warner-Lambert Company 2,N6 -disubstituted adenosines, derivatives and methods of use
ZA857998B (en) * 1984-10-26 1986-05-28 Warner Lambert Co N6-substituted adenosines
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4683223A (en) * 1985-09-09 1987-07-28 Warner-Lambert Company N6 -Benzopyrano-and benzothiopyrano adenosines and methods of use
AU579412B2 (en) * 1984-10-26 1988-11-24 Warner-Lambert Company N` - substituted adenosines
US4593019A (en) * 1984-10-26 1986-06-03 Warner-Lambert Company N6 -tricyclic adenosines
US4626526A (en) * 1984-10-26 1986-12-02 Warner-Lambert Company (S)-N6 -2-hydroxypropyladenosines
AU8274187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
AU8276187A (en) * 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
US4843066A (en) * 1986-11-27 1989-06-27 Nippon Zoki Pharmaceutical Co., Ltd. Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
US4837207A (en) * 1987-05-13 1989-06-06 Warner-Lambert Company Diastereoisomers of n6 -endo-bicyclo[2.2.1]heptyladenosine as antihypertensives with selective action
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物

Also Published As

Publication number Publication date
USRE37077E1 (en) 2001-02-27
ATE112285T1 (de) 1994-10-15
JPH0725785B2 (ja) 1995-03-22
EP0378518A2 (de) 1990-07-18
DE69012840D1 (de) 1994-11-03
US4985409A (en) 1991-01-15
EP0378518B1 (de) 1994-09-28
JPH02184696A (ja) 1990-07-19
EP0378518A3 (en) 1990-12-27
DK0378518T3 (da) 1994-10-24
ES2064700T3 (es) 1995-02-01

Similar Documents

Publication Publication Date Title
DE69012840D1 (de) Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben.
ES2066000T3 (es) Compuestos derivados de pirimidinediona, metodo de produccion de los mismos y agentes antirritmicos que los contienen.
EP0632031A4 (de)
DE69725585D1 (de) Phenylalkylcarbonsäure-derivate
FI953710A (fi) Uusia pyrrolokarbatsoleja
ES2046641T3 (es) Composicion antitumoral.
ES2035915T3 (es) Agentes antiarritmicos n-fenetil-aminoalquil-benzamida.
NO904031L (no) Fremgangsmaate ved fremstilling av beta-karbonyl-karboksyamider av 1,3-tiazolidiner.
DK0427518T3 (da) NMDA-blokerende forbindelser, farmaceutiske præparater, deres fremstilling og anvendelse
EP0407621A4 (en) Benzothiazole derivatives
DK0420224T3 (da) Anthihepatopatisk middel
FI883507A (fi) Naftotiazepinderivat och deras framstaellning.
ATE151987T1 (de) Verwendung von 3-pyridazinone zur verringerung der blutplätchenzahl
FI903967A0 (fi) Nya imidazolderivat.
KR890009886A (ko) 심기능 부전의 예방 및 치료제
DE3781044T2 (de) Prophylaktische und heilende zusammensetzung enthaltende eine 8-chlorbenzothiazepin-verbindung und dessen verwendung.
DE3782229T2 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
DK0455899T3 (da) Prostaglandin I-analog

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee